Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid‐specific lectin immunoassay
Authors:
- 20 June 2002
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 22 (8) , 656-662
Abstract
In a series of 54 cases of pregnancies complicated by Down syndrome and 224 unaffected pregnancies we examined maternal serum levels of hyperglycosylated human chorionic gonadotrophin (HhCG) in samples collected in the first trimester (11–13 weeks) using a sialic acid‐specific lectin immunoassay. We compared these levels with those of other potential first trimester serum markers [free β‐hCG, pregnancy‐associated plasma protein A (PAPP‐A) and total hCG (ThCG)] and modeled detection rates and false‐positive rates of various biochemical markers in conjunction with fetal nuchal translucency (NT) and maternal age using an maternal age standardized population. Maternal serum HhCG in cases of Down syndrome were significantly elevated (median MoM 1.97) with 24/54 (44%) of cases above the 95th centile for unaffected pregnancies. Free β‐hCG was also elevated (median MoM 2.09) with 33% of cases above the 95th centile. PAPP‐A levels were reduced (median MoM 0.47) with 38% below the 5th centile. ThCG levels, whilst elevated (median MoM 1.34), had only 20% of cases above the 95th centile. Maternal serum HhCG levels were not correlated with fetal NT but showed significant correlation with ThCG and free β‐hCG and with PAPP‐A in the Down syndrome group (r=0.536). Maternal serum HhCG levels in cases with Down syndrome had a significant correlation with gestational age, increasing as the gestation increased. When HhCG was combined together with fetal NT, PAPP‐A and maternal age, at a 5% false‐positive rate the modeled detection rate was 83%, some 6% lower than when free β‐hCG was used and some 4% better than when ThCG was used. Maternal serum HhCG is unlikely to be of additional value when screening for Down syndrome in the first trimester. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 28 references indexed in Scilit:
- Collaborative study of maternal urine β -core human chorionic gonadotrophin screening for Down syndromePrenatal Diagnosis, 1999
- Maternal urine hyperglycosylated hCG in pregnancies with Down syndromePrenatal Diagnosis, 1999
- Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCGPrenatal Diagnosis, 1999
- Urinary free beta hCG, beta core fragment and total oestriol as markers of Down syndrome in the second trimester of pregnancyPrenatal Diagnosis, 1999
- Development and Characterization of Antibodies to a Nicked and Hyperglycosylated Form of hCG from a Choriocarcinoma Patient: Generation of Antibodies That Differentiate Between Pregnancy hCG and Choriocarcinoma hCGEndocrine, 1999
- Hyperglycosylated hcg, a potential alternative to hcg in Down syndrome screeningPrenatal Diagnosis, 1998
- Oligosaccharide variants of hCG-related molecules: potential screening markers for Downs syndromePrenatal Diagnosis, 1997
- Urinary multiple marker screening for down's syndromePrenatal Diagnosis, 1995
- Urinary β‐core human chorionic gonadotrophin: A new approach to Down's syndrome screeningPrenatal Diagnosis, 1994
- Impact of a Regional Screening Programme Using Maternal Serum a Fetoprotein (AFP) and Human Chorionic Gonadotrophin (hCG) on the Birth Incidence of Down's Syndrome in the West of ScotlandJournal of Medical Screening, 1994